Palynziq

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
IB/0042/G	This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits	09/07/2024	n/a		

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits				
R/0038	Renewal of the marketing authorisation.	22/02/2024	19/04/2024	SmPC and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Palynziq in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.
IB/0041	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	03/04/2024	n/a		
II/0039/G	This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer	08/02/2024	19/04/2024	Annex II	The Annex II has been updated to include the manufacturer(s) of the biological active substance(s) Boehringer Ingelheim RCV GmbH & Co KG (BI), Dr.-Boehringer-Gasse 5-11, Meidling, Vienna, 1121 Austria.

IB/0036	B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line)	19/09/2023	n/a		
IA/0037	A.7 - Administrative change - Deletion of manufacturing sites	25/07/2023	n/a		
IB/0035	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	06/07/2023	n/a		
IB/0034	B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place	15/06/2023	n/a		
PSUSA/10761 /202205	Periodic Safety Update EU Single assessment - pegvaliase	26/01/2023	24/03/2023	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10761/202205.
IA/0033	B.II.f.1.e - Stability of FP - Change to an approved stability protocol	16/02/2023	n/a		
IB/0032	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	04/01/2023	n/a		

IB/0030	B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place	09/12/2022	n/a		
IB/0031	B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place	08/11/2022	n/a		
IB/0028/G	This was an application for a group of variations. B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.e.1.z - Change in immediate packaging of the finished product - Other variation	07/06/2022	24/03/2023	SmPC	
IB/0027	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	30/05/2022	n/a		
IB/0025	B.I.z - Quality change - Active substance - Other variation	19/04/2022	n/a		

PSUSA/10761 /202105	Periodic Safety Update EU Single assessment - pegvaliase	27/01/2022	24/03/2022	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10761/202105.
IB/0026	B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits	21/02/2022	n/a		
IB/0023	B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation	02/12/2021	n/a		
II/0024	B.II.g.2 - Introduction of a post approval change management protocol related to the finished product	25/11/2021	n/a		
II/0019	B.I.e.1.a - Introduction of a new design space or extension of an approved design space for the AS - One unit operation in the manufacturing process of the AS including the resulting IPCs and/or test procedures	02/09/2021	n/a		
PSUSA/10761 /202011	Periodic Safety Update EU Single assessment - pegvaliase	24/06/2021	18/08/2021	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10761/202011.
IB/0020/G	This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor	05/08/2021	n/a		

	changes to an approved test procedure B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS				
IB/0021	B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product	02/08/2021	n/a		
II/0017	B.I.a.1.e (Type II): to introduce an additional site responsible for the preparation, testing and storage of the WCB. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product	15/04/2021	n/a		
PSUSA/10761 /202005	Periodic Safety Update EU Single assessment - pegvaliase	28/01/2021	26/03/2021	SmPC	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10761/202005.
II/0014	B.I.e.2 - Introduction of a post approval change management protocol related to the AS	04/02/2021	n/a		
II/0015	Submission of the final report from the non-clinical study BMN-165-18-080 listed as a category 3 study in the RMP.	10/12/2020	n/a		

	C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority				
IB/0013/G	This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product	30/09/2020	n/a		
IB/0011/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting	14/09/2020	n/a		

	material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate				
II/0007/G	This was an application for a group of variations. Update of sections 4.4, 4.8 and 5.1 of the SmPC based on final results from studies 1655-003, a long-term extension of a Phase 2, open-label, dose-finding study and 165-302 a Phase 3, randomised, double-blind, placebo-controlled, four-arm, discontinuation study which are listed in the RMP as category 3 studies. The RMP version 2.0 has also been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	03/09/2020	26/03/2021	SmPC	During long-term pegvaliase treatment, sustained clinically meaningful blood phenylalanine lowering effect was observed; and most adverse events rates decreased.
PSUSA/10761 /201911	Periodic Safety Update EU Single assessment - pegvaliase	11/06/2020	n/a		PRAC Recommendation - maintenance

IB/0010	B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation	02/06/2020	n/a		
IB/0009/G	This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	04/05/2020	n/a		
II/0002	B.II.g.2 - Introduction of a post approval change management protocol related to the finished product	16/01/2020	n/a		
PSUSA/10761 /201905	Periodic Safety Update EU Single assessment - pegvaliase	16/01/2020	n/a		PRAC Recommendation - maintenance
IG/1141	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release -	12/12/2019	n/a		

	Not including batch control/testing				
IAIN/0006/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	11/12/2019	n/a		
IB/0004	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	07/11/2019	n/a		
IB/0003	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	08/10/2019	n/a		